Navigation Links
Quest Diagnostics Incorporated Announces Proposed Senior Notes Offering
Date:3/21/2011

MADISON, N.J., March 21, 2011 /PRNewswire/ -- Quest Diagnostics Incorporated (the "Company") (NYSE:  DGX), the world's leading provider of diagnostic testing, information and services, announced today that it intends to offer $1,250,000,000 in aggregate principal amount of four series of senior notes in a public offering made under a shelf registration statement filed with the Securities and Exchange Commission, subject to market and other conditions.  The notes will be fully and unconditionally guaranteed on a senior, unsecured basis by certain of the Company's domestic, wholly owned subsidiaries.

The issuance of the notes will be subject to customary closing conditions.  The Company intends to use the net proceeds from the offering to fund the purchase price and related transaction costs of its acquisition of Athena Diagnostics, Inc. and to repay outstanding indebtedness under its senior unsecured revolving credit facility and secured receivables credit facility.  Morgan Stanley & Co. Incorporated, Goldman, Sachs & Co., RBS Securities Inc., J.P. Morgan Securities LLC and Wells Fargo Securities, LLC will be joint bookrunning managers for the debt offering.  When available, copies of the preliminary prospectus supplement and the accompanying base prospectus for the offering can be obtained from Morgan Stanley & Co. Incorporated tollfree at (866) 7181649, Goldman, Sachs & Co. tollfree at (866) 471-2526, RBS Securities Inc. tollfree at (866) 8842071, J.P. Morgan Securities LLC at (212) 834-4533 and Wells Fargo Securities, LLC toll-free at (800) 326-5897.

This press release shall not constitute an offer to sell or a solicitation of an offer to purchase any of these securities and shall not constitute an offer, solicitation or sale in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful.  This offering may be made only by means of a prospectus supplement and accompanying base prospectus.

About Quest Diagnostics

Quest Diagnostics is the world's leading provider of diagnostic testing, information and services that patients and doctors need to make better healthcare decisions.  The company offers the broadest access to diagnostic testing services through its network of laboratories and patient service centers, and provides interpretive consultation through its extensive medical and scientific staff.  Quest Diagnostics is a pioneer in developing innovative diagnostic tests and advanced healthcare information technology solutions that help improve patient care.

The statements in this press release which are not historical facts may be forwardlooking statements.  Readers are cautioned not to place undue reliance on forwardlooking statements, which speak only as of the date that they are made and which reflect management's current estimates, projections, expectations or beliefs and which involve risks and uncertainties that could cause actual results and outcomes to be materially different.  Risks and uncertainties that may affect the future results of the company include, but are not limited to, adverse results from pending or future government investigations, lawsuits or private actions, the competitive environment, changes in government regulations, changing relationships with customers, payers, suppliers and strategic partners and other factors discussed in "Business," "Risk Factors," "Cautionary Factors that May Affect Future Results," "Legal Proceedings," "Management's Discussion and Analysis of Financial Condition and Results of Operations," and "Quantitative and Qualitative Disclosures About Market Risk" in the Company's 2010 Annual Report on Form 10K and the Company's 2011 Current Reports on Form 8K.

CONTACTS
Kathleen Valentine, Investors, 9735202900
Wendy Bost, Media, 9735202800


'/>"/>
SOURCE Quest Diagnostics Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Quest Diagnostics to Acquire Celera, Strengthening Position as Worlds Leading Innovator in Molecular Diagnostics and Development
2. Questcor Pharmaceuticals to Present at the Barclays Capital Global Healthcare Conference
3. CardioGenics Requests Stockholders to Participate in Stockholder Questionnaires
4. Questcor Pharmaceuticals Selects BDO USA as its Auditor
5. Questcor Reports 2010 Financial Results
6. Physicians Who Treat Obesity Question FDA Rejection of Contrave
7. Questcor to Report Fourth Quarter and Full Year 2010 Earnings and Conduct Conference Call on February 23, 2011
8. Quest Diagnostics Announces Pricing in Offering of Common Stock by the Companys Largest Shareholder
9. Quest Diagnostics Agrees to Repurchase 15.4 Million Shares From Largest Shareholder
10. Quest Diagnostics to Release Fourth Quarter and Full Year 2010 Financial Results
11. Questcor Pharmaceuticals Reports Strong Finish to 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... , April 19, 2017  New research provides evidence that ... Parkinson,s, according to a study released today that will be ... Meeting in Boston , April 22 ... the treatment of Parkinson,s disease, the oral drug levodopa has ... and longevity. But as the disease progresses, the effects of ...
(Date:4/18/2017)... Ohio , April 18, 2017  Cardinal Health ... Non-GAAP 1 fiscal 2017 earnings per share (EPS) ... and 2019.  This is in conjunction with this morning,s ... Deep Vein Thrombosis and Nutritional Insufficiency businesses. ... from continuing operations will be at the bottom of ...
(Date:4/18/2017)... 2017 Research and Markets has announced the ... to their offering. ... arthroscopy devices market to grow at a CAGR of 6.35% during ... Market 2017-2021, has been prepared based on an in-depth market analysis ... and its growth prospects over the coming years. The report also ...
Breaking Medicine Technology:
(Date:4/21/2017)... PA (PRWEB) , ... April 21, 2017 , ... ... firm in Allegheny County that offers services to communities throughout the greater Pittsburgh ... in a charity drive to provide adaptive bicycles for differently-abled children. , Variety ...
(Date:4/21/2017)... ... ... The Patient Advocacy Community of The Beryl Institute presented Eve DeVaro, Director, ... Advocacy Award in recognition of her extraordinary contributions to the field of patient ... Beryl Institute’s annual Patient Experience Conference on March 20 in Denver, Colorado. ...
(Date:4/21/2017)... ... 21, 2017 , ... Crossover Symmetry , an evidence ... active lifestyle company that provides Human Performance Training and education to tactical athletes. ... responders, military officers and others in service through the development and conditioning of ...
(Date:4/21/2017)... ... 2017 , ... Airway Management, the medical device manufacturer of ... and well renowned Asian distributor, Discovery Sleep. The agreement involves the ... and will stabilize and strengthen Airway’s presence with a dedicated, reputable medical device ...
(Date:4/21/2017)... ... April 21, 2017 , ... ... candidates to serve on its Accreditation and Standards Committees to support the ... is improving image quality and reducing patient radiation dose,” reports Eliot Siegel, ...
Breaking Medicine News(10 mins):